Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer.
Mehanna H, Gaunt P, Kong A, Hartley A, Sanghera P, Forster M, Sen M, Paleri V, Fong C, Geropantas D, Srinivasan D, Garikipati S, Moleron R, Casswell G, Aynsley E, Ward A, O'Toole L, Mirza A, Firth C, Humphreys I, Fulton-Lieuw T, Roques T, Nankivell P. Mehanna H, et al. Among authors: gaunt p. Trials. 2024 Jan 15;25(1):50. doi: 10.1186/s13063-023-07881-1. Trials. 2024. PMID: 38221636 Free PMC article.
PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial.
Nankivell P, Gaunt P, Gaunt C, Sissons J, Liaskou E, Jefferson Y, Fulton-Lieuw T, Mittal S, Mehanna H; PETNECK2 Research Team. Nankivell P, et al. Among authors: gaunt p. BMC Cancer. 2024 Jul 10;24(1):823. doi: 10.1186/s12885-024-12470-9. BMC Cancer. 2024. PMID: 38987693 Free PMC article.
Correction: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial.
Nankivell P, Gaunt P, Gaunt C, Sissons J, Liaskou E, Jefferson Y, Fulton-Lieuw T, Mittal S, Mehanna H; PETNECK2 Research Team. Nankivell P, et al. Among authors: gaunt p. BMC Cancer. 2024 Jul 18;24(1):861. doi: 10.1186/s12885-024-12639-2. BMC Cancer. 2024. PMID: 39026293 Free PMC article. No abstract available.
Predicting radiotherapy response, Toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose-volume constraints development: a study protocol.
Simões R, Gulliford S, Seddon B, Dehbi HM, Robinson M, Forsyth S, Hughes A, Gaunt P, Nguyen TG, Elston S, Mohammed K, Zaidi S, Miles E, Hoskin P, Harrington K, Miah A. Simões R, et al. Among authors: gaunt p. BMJ Open. 2024 Aug 9;14(8):e083617. doi: 10.1136/bmjopen-2023-083617. BMJ Open. 2024. PMID: 39122389 Free PMC article.
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata.
Woll PJ, Gaunt P, Gaskell C, Young R, Benson C, Judson IR, Seddon BM, Marples M, Ali N, Strauss SJ, Lee A, Hughes A, Kaur B, Hughes D, Billingham L. Woll PJ, et al. Among authors: gaunt p. Br J Cancer. 2023 Oct;129(9):1490-1499. doi: 10.1038/s41416-023-02416-6. Epub 2023 Sep 8. Br J Cancer. 2023. PMID: 37684354 Free PMC article. Clinical Trial.
Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma.
Forker LJ, Bibby B, Yang L, Lane B, Irlam J, Mistry H, Khan M, Valentine H, Wylie J, Shenjere P, Leahy M, Gaunt P, Billingham L, Seddon BM, Grimer R, Robinson M, Choudhury A, West C. Forker LJ, et al. Among authors: gaunt p. Br J Cancer. 2023 Jun;128(12):2307-2317. doi: 10.1038/s41416-023-02265-3. Epub 2023 Apr 21. Br J Cancer. 2023. PMID: 37085598 Free PMC article.
Animal drug shortages limit veterinary therapeutic options and introduce artifacts in antimicrobial sales reporting.
Members of the AVMA Committee on Antimicrobials:; Robbins RC, Singer RS, Innes GK, Plummer PJ, Apley MD, Gaunt PS, Papich MG, Granick J, Marshall ES, Smith DR, Frey E, Cervantes HM, Beaudoin AL, Canon AJ, Brookshire C, Buckley M, Whaley J, Schnabel L, Costin M. Members of the AVMA Committee on Antimicrobials:, et al. Among authors: gaunt ps. J Am Vet Med Assoc. 2024 Jan 3;262(4):576-579. doi: 10.2460/javma.23.10.0603. Print 2024 Apr 1. J Am Vet Med Assoc. 2024. PMID: 38171090
76 results